Topical cosmetic use appears to be well tolerated for most individuals, though long-term systemic applications have not been fully studied
Data from the Phase 2 programme (NEJM, 2023) provide an initial picture of its tolerability, which broadly mirrors that of other incretin-based therapies, with some additional considerations related to its glucagon receptor activity
Cold-chain risk: International transit increases temperature exposure, which matters more for newer complex peptides
Its name comes from its ability to promote delta wave activity, the slow brainwaves characteristic of deep sleep
Abiri B, Koohi F, Ebadinejad A, Valizadeh M, Hosseinpanah F (2022) Transition from metabolically healthy to unhealthy overweight/obesity and risk of cardiovascular disease incidence: a systematic review and meta-analysis
It does so by stimulating insulin release and reducing glucagon, among other actions